Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...
A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...
In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...
Zacks Small Cap Research on MSN11d
INAB: Introducing INB-600, A γδ T Cell Engager PlatformINAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and ...
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback